Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/1060
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | GIGANTE, Alexandre Duarte | - |
dc.contributor.author | BOND, David J. | - |
dc.contributor.author | LAFER, Beny | - |
dc.contributor.author | LAM, Raymond W. | - |
dc.contributor.author | YOUNG, L. Trevor | - |
dc.contributor.author | YATHAM, Lakshmi N. | - |
dc.date.accessioned | 2013-07-30T15:18:50Z | - |
dc.date.available | 2013-07-30T15:18:50Z | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | BIPOLAR DISORDERS, v.14, n.5, p.478-487, 2012 | - |
dc.identifier.issn | 1398-5647 | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/1060 | - |
dc.description.abstract | Gigante AD, Bond DJ, Lafer B, Lam RW, Young LT, Yatham LN. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disord 2012: 14: 478487. (c) 2012 The Authors. Journal compilation (c) 2012 John Wiley & Sons A/S. Objectives: Bipolar disorder (BD) is a common and highly disabling disease characterized by substantial cognitive and functional impairment. The exact neurobiological mechanisms underlying the expression of symptoms in this condition remain unknown but there is growing evidence that glutamate might play an important role. Using proton magnetic resonance spectroscopy (1H-MRS), a number of studies have examined brain glutamate/glutamine levels in patients with bipolar disorder, but they have produced conflicting results. The objective of this paper was to conduct a systematic review and meta-analysis of the literature on brain glutamate/glutamine in BD as measured by 1H-MRS. Methods: A Medline search for the period January 1980April 2010 was conducted to identify published studies that used 1H-MRS to measure glutamate + glutamine (Glx), the Glx/creatine (Cr) ratio, glutamate (Glu), or the Glu/Cr ratio in any brain region in adult or child/adolescent patients with BD and healthy subjects. A meta-analysis of the pooled data was conducted. Results: BD patients were found to have increased Glx compared to healthy subjects when all brain areas were combined. This finding remained true in medicated and non-medicated patients, and in frontal brain areas in adults. There was a non-significant trend (p = 0.09) for an increase in whole-brain Glx/Cr and Glu in patients compared with healthy subjects. No significant difference was found in Glu/Cr. Conclusions: The results of this meta-analysis suggest that brain Glx levels are elevated in BD patients and support the idea that glutamate might play an important role in the pathophysiology of BD. | - |
dc.description.sponsorship | University of Oeste Paulista (UNOESTE), Presidente Prudente, Sao Paulo, Brazil | - |
dc.description.sponsorship | Department of Psychiatry, University of British Columbia, Vancouver, Canada | - |
dc.description.sponsorship | Canadian Institutes of Health Research (CIHR) | - |
dc.description.sponsorship | UBC Institute of Mental Health/Coast Capital Depression Research Fund | - |
dc.description.sponsorship | Canadian Network for Mood and Anxiety Treatments (CANMAT) | - |
dc.description.sponsorship | Canadian Psychiatric Association | - |
dc.description.sponsorship | AstraZeneca | - |
dc.description.sponsorship | Janssen-Ortho | - |
dc.description.sponsorship | Bristol-Myers Squibb | - |
dc.description.sponsorship | Otsuka | - |
dc.description.sponsorship | Biovail | - |
dc.description.sponsorship | Canadian Institutes of Health Research | - |
dc.description.sponsorship | Eli Lilly Co. | - |
dc.description.sponsorship | Litebook Company | - |
dc.description.sponsorship | Lundbeck | - |
dc.description.sponsorship | Lundbeck Institute | - |
dc.description.sponsorship | Mochida | - |
dc.description.sponsorship | Pfizer | - |
dc.description.sponsorship | Servier | - |
dc.description.sponsorship | St. Jude's Medical | - |
dc.description.sponsorship | Takeda | - |
dc.description.sponsorship | UBC Institute of Mental Health/Coast Capital Savings | - |
dc.description.sponsorship | Forest | - |
dc.description.sponsorship | GlaxoSmithKline | - |
dc.description.sponsorship | Janssen | - |
dc.description.sponsorship | Michael Smith Foundation for Health Research | - |
dc.description.sponsorship | Novartis | - |
dc.description.sponsorship | Ranbaxy | - |
dc.description.sponsorship | Stanley Foundation | - |
dc.language.iso | eng | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.relation.ispartof | Bipolar Disorders | - |
dc.rights | restrictedAccess | - |
dc.subject | bipolar disorder | - |
dc.subject | glutamate | - |
dc.subject | glutamate plus glutamine (Glx) | - |
dc.subject | meta-analysis | - |
dc.subject | proton magnetic resonance spectroscopy | - |
dc.subject.other | dorsolateral prefrontal cortex | - |
dc.subject.other | cellular plasticity cascades | - |
dc.subject.other | anterior cingulate cortex | - |
dc.subject.other | excitatory amino-acids | - |
dc.subject.other | pituitary-adrenal axis | - |
dc.subject.other | mitochondrial dysfunction | - |
dc.subject.other | psychiatric-disorders | - |
dc.subject.other | cortical glutamate | - |
dc.subject.other | oxidative stress | - |
dc.subject.other | mood disorders | - |
dc.title | Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis | - |
dc.type | article | - |
dc.rights.holder | Copyright WILEY-BLACKWELL | - |
dc.identifier.doi | 10.1111/j.1399-5618.2012.01033.x | - |
dc.identifier.pmid | 22834460 | - |
dc.subject.wos | Clinical Neurology | - |
dc.subject.wos | Neurosciences | - |
dc.subject.wos | Psychiatry | - |
dc.type.category | review | - |
dc.type.version | publishedVersion | - |
hcfmusp.author.external | BOND, David J.:Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada | - |
hcfmusp.author.external | LAM, Raymond W.:Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada | - |
hcfmusp.author.external | YOUNG, L. Trevor:Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON, Canada | - |
hcfmusp.author.external | YATHAM, Lakshmi N.:Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada | - |
hcfmusp.description.beginpage | 478 | - |
hcfmusp.description.endpage | 487 | - |
hcfmusp.description.issue | 5 | - |
hcfmusp.description.volume | 14 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | 2-s2.0-84864388823 | - |
hcfmusp.origem.id | WOS:000306805000003 | - |
hcfmusp.publisher.city | HOBOKEN | - |
hcfmusp.publisher.country | USA | - |
hcfmusp.relation.reference | Aalto S, 2005, PSYCHOPHARMACOLOGY, V182, P375, DOI 10.1007/s00213-005-0092-6 | - |
hcfmusp.relation.reference | ALTAMURA CA, 1993, AM J PSYCHIAT, V150, P1731 | - |
hcfmusp.relation.reference | Andreazza AC, 2008, J AFFECT DISORDERS, V111, P135, DOI 10.1016/j.jad.2008.04.013 | - |
hcfmusp.relation.reference | Arnone D, 2009, BRIT J PSYCHIAT, V195, P194, DOI 10.1192/bjp.bp.108.059717 | - |
hcfmusp.relation.reference | Atmaca M, 2009, INT REV PSYCHIATR, V21, P410, DOI 10.1080/09540260902962206 | - |
hcfmusp.relation.reference | Barker PB, 2001, MAGNET RESON MED, V45, P765, DOI 10.1002/mrm.1104 | - |
hcfmusp.relation.reference | Beneyto M, 2006, SYNAPSE, V60, P585, DOI 10.1002/syn.20329 | - |
hcfmusp.relation.reference | Bhagwagar Z, 2007, BIOL PSYCHIAT, V61, P806, DOI 10.1016/j.biopsych.2006.08.048 | - |
hcfmusp.relation.reference | Carr DB, 2000, J NEUROSCI, V20, P3864 | - |
hcfmusp.relation.reference | Castillo M, 2000, AM J NEURORADIOL, V21, P832 | - |
hcfmusp.relation.reference | Chuang DM, 2002, BIPOLAR DISORD, V4, P129, DOI 10.1034/j.1399-5618.2002.01179.x | - |
hcfmusp.relation.reference | Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5 | - |
hcfmusp.relation.reference | Colla M, 2009, MOL PSYCHIATR, V14, P696, DOI 10.1038/mp.2008.26 | - |
hcfmusp.relation.reference | Cousins DA, 2009, BIPOLAR DISORD, V11, P787, DOI 10.1111/j.1399-5618.2009.00760.x | - |
hcfmusp.relation.reference | Daban C, 2005, PSYCHIAT CLIN N AM, V28, P469, DOI 10.1016/j.psc.2005.01.005 | - |
hcfmusp.relation.reference | Dager SR, 2004, ARCH GEN PSYCHIAT, V61, P450, DOI 10.1001/archpsyc.61.5.450 | - |
hcfmusp.relation.reference | Davanzo P, 2001, NEUROPSYCHOPHARMACOL, V24, P359, DOI 10.1016/S0893-133X(00)00207-4 | - |
hcfmusp.relation.reference | Davanzo P, 2003, AM J PSYCHIAT, V160, P1442, DOI 10.1176/appi.ajp.160.8.1442 | - |
hcfmusp.relation.reference | Del Arco A, 2009, J NEURAL TRANSM, V116, P941, DOI 10.1007/s00702-009-0243-8 | - |
hcfmusp.relation.reference | DelBello MP, 2006, NEUROPSYCHOPHARMACOL, V31, P1264, DOI 10.1038/sj.npp.1300950 | - |
hcfmusp.relation.reference | Dong XX, 2009, ACTA PHARMACOL SIN, V30, P379, DOI 10.1038/aps.2009.24 | - |
hcfmusp.relation.reference | Frey BN, 2007, BIPOLAR DISORD, V9, P119, DOI 10.1111/j.1399-5618.2007.00454.x | - |
hcfmusp.relation.reference | Frye MA, 2007, PSYCHIAT RES-NEUROIM, V154, P259, DOI 10.1016/j.pscychresns.2006.11.003 | - |
hcfmusp.relation.reference | Frye MA, 2007, NEUROPSYCHOPHARMACOL, V32, P2490, DOI 10.1038/sj.npp.1301387 | - |
hcfmusp.relation.reference | Gigante A. D., 2010, INT J NEUROPSYCHOPH, V23, P1 | - |
hcfmusp.relation.reference | Gonul AS, 2009, INT REV PSYCHIATR, V21, P323, DOI 10.1080/09540260902962131 | - |
hcfmusp.relation.reference | Goodwin FK, 2007, MANIC DEPRESSIVE ILL | - |
hcfmusp.relation.reference | GRUETTER R, 1994, J NEUROCHEM, V63, P1377 | - |
hcfmusp.relation.reference | Hashimoto K, 2007, BIOL PSYCHIAT, V62, P1310, DOI 10.1016/j.biopsych.2007.03.017 | - |
hcfmusp.relation.reference | Hashimoto R, 2002, J NEUROCHEM, V80, P589, DOI 10.1046/j.0022-3042.2001.00728.x | - |
hcfmusp.relation.reference | Hassel B., 2006, BASIC NEUROCHEMISTRY, P267 | - |
hcfmusp.relation.reference | Heath PR, 2002, MUSCLE NERVE, V26, P438, DOI 10.1002/mus.10186 | - |
hcfmusp.relation.reference | Hoekstra R, 2006, EUR NEUROPSYCHOPHARM, V16, P71, DOI 10.1016/j.euroneuro.2005.06.003 | - |
hcfmusp.relation.reference | Itokawa M, 2003, NEUROSCI LETT, V345, P53, DOI 10.1016/S0304-3940(03)00501-9 | - |
hcfmusp.relation.reference | Kapczinski Flavio, 2008, Expert Rev Neurother, V8, P1101, DOI 10.1586/14737175.8.7.1101 | - |
hcfmusp.relation.reference | Kapczinski F, 2011, J PSYCHIATR RES, V45, P156, DOI [10.1016/j.jpsychires.2010.05.015, 10.1016/j.psychires.2010.05.015] | - |
hcfmusp.relation.reference | Kato T, 2000, BIPOLAR DISORD, V2, P180, DOI 10.1034/j.1399-5618.2000.020305.x | - |
hcfmusp.relation.reference | Kato T, 2008, TRENDS NEUROSCI, V31, P495, DOI 10.1016/j.tins.2008.07.007 | - |
hcfmusp.relation.reference | Kaufman RE, 2009, PROG NEURO-PSYCHOPH, V33, P427, DOI 10.1016/j.pnpbp.2008.12.025 | - |
hcfmusp.relation.reference | Kim YK, 2007, J AFFECT DISORDERS, V104, P91, DOI 10.1016/j.jad.2007.02.018 | - |
hcfmusp.relation.reference | Kristiansen LV, 2005, SCHIZOPHR RES, V78, P87, DOI 10.1016/j.schres.2005.06.012 | - |
hcfmusp.relation.reference | MacQueen GM, 2001, ACTA PSYCHIAT SCAND, V103, P163, DOI 10.1034/j.1600-0447.2001.00059.x | - |
hcfmusp.relation.reference | Martinowich K, 2009, J CLIN INVEST, V119, P726, DOI 10.1172/JCI37703 | - |
hcfmusp.relation.reference | McCullumsmith RE, 2007, BRAIN RES, V1127, P108, DOI 10.1016/j.brainres.2006.09.011 | - |
hcfmusp.relation.reference | Merikangas KR, 2007, ARCH GEN PSYCHIAT, V64, P543, DOI 10.1001/archpsyc.64.5.543 | - |
hcfmusp.relation.reference | Michael N, 2003, PSYCHOPHARMACOLOGY, V168, P344, DOI 10.1007/s00213-003-1440-z | - |
hcfmusp.relation.reference | Michael N, 2009, PSYCHIAT RES-NEUROIM, V172, P78, DOI 10.1016/j.pscychresns.2009.01.002 | - |
hcfmusp.relation.reference | MOGHADDAM B, 1993, J NEUROCHEM, V60, P1650, DOI 10.1111/j.1471-4159.1993.tb13387.x | - |
hcfmusp.relation.reference | Moore CM, 2007, J AM ACAD CHILD PSY, V46, P524, DOI 10.1097/chi.0b013e31802f5f2c | - |
hcfmusp.relation.reference | Mundo E, 2003, MOL PSYCHIATR, V8, P241, DOI 10.1038/sj.mp.4001218 | - |
hcfmusp.relation.reference | Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740 | - |
hcfmusp.relation.reference | Nery FG, 2010, J PSYCHIATR RES, V44, P278, DOI 10.1016/j.jpsychires.2009.09.006 | - |
hcfmusp.relation.reference | Olvera RL, 2007, J CHILD ADOL PSYCHOP, V17, P461, DOI 10.1089/cap.2007.0102 | - |
hcfmusp.relation.reference | Ongur D, 2008, BIOL PSYCHIAT, V64, P718, DOI 10.1016/j.biopsych.2008.05.014 | - |
hcfmusp.relation.reference | Rajkowska G, 2002, BIPOLAR DISORD, V4, P105, DOI 10.1034/j.1399-5618.2002.01149.x | - |
hcfmusp.relation.reference | Rao JS, 2007, J NEUROCHEM, V102, P1918, DOI 10.1111/j.1471-4159.2007.04648.x | - |
hcfmusp.relation.reference | Rao JS, 2010, MOL PSYCHIATR, V15, P384, DOI 10.1038/mp.2009.47 | - |
hcfmusp.relation.reference | Rosa AR, 2010, VALUE HEALTH, V13, P984, DOI 10.1111/j.1524-4733.2010.00768.x | - |
hcfmusp.relation.reference | Ross B, 2001, ANAT REC, V265, P54, DOI 10.1002/ar.1058 | - |
hcfmusp.relation.reference | Sanacora G, 2008, NAT REV DRUG DISCOV, V7, P426, DOI 10.1038/nrd2462 | - |
hcfmusp.relation.reference | Schloesser RJ, 2008, NEUROPSYCHOPHARMACOL, V33, P110, DOI 10.1038/sj.npp.1301575 | - |
hcfmusp.relation.reference | Schmider J, 1995, BIOL PSYCHIAT, V38, P797, DOI 10.1016/0006-3223(95)00064-X | - |
hcfmusp.relation.reference | Schubert MI, 2008, J PSYCHIATR RES, V42, P902, DOI 10.1016/j.jpsychires.2007.10.003 | - |
hcfmusp.relation.reference | Senaratne R, 2009, PSYCHIAT RES-NEUROIM, V172, P205, DOI 10.1016/j.pscychresns.2008.07.007 | - |
hcfmusp.relation.reference | Sesack SR, 2003, ANN NY ACAD SCI, V1003, P36, DOI 10.1196/annals.1300.066 | - |
hcfmusp.relation.reference | Shao L, 2005, BIOL PSYCHIAT, V58, P879, DOI 10.1016/j.biopsych.2005.04-052 | - |
hcfmusp.relation.reference | Singh M, 2010, PSYCHIAT RES-NEUROIM, V182, P165, DOI 10.1016/j.pscychresns.2010.01.003 | - |
hcfmusp.relation.reference | Stork C, 2005, MOL PSYCHIATR, V10, P900, DOI 10.1038/sj.mp.4001711 | - |
hcfmusp.relation.reference | Tohen M, 2000, AM J PSYCHIAT, V157, P220, DOI 10.1176/appi.ajp.157.2.220 | - |
hcfmusp.relation.reference | Torres IJ, 2010, J CLIN PSYCHIAT, V71, P1234, DOI 10.4088/JCP.08m04997yel | - |
hcfmusp.relation.reference | Wang JF, 2009, BIPOLAR DISORD, V11, P523, DOI 10.1111/j.1399-5618.2009.00717.x | - |
hcfmusp.relation.reference | Watson S, 2004, BRIT J PSYCHIAT, V184, P496, DOI 10.1192/bjp.184.6.496 | - |
hcfmusp.relation.reference | Zarate CA, 2006, BIOL PSYCHIAT, V59, P1006, DOI 10.1016/j.biopsych.2005.10.021 | - |
dc.description.index | MEDLINE | - |
hcfmusp.remissive.sponsorship | AstraZeneca | - |
hcfmusp.remissive.sponsorship | Bristol-Myers Squibb | - |
hcfmusp.remissive.sponsorship | CIHR | - |
hcfmusp.remissive.sponsorship | GlaxoSmithKline | - |
hcfmusp.remissive.sponsorship | Janssen | - |
hcfmusp.remissive.sponsorship | Lilly | - |
hcfmusp.remissive.sponsorship | Lundbeck | - |
hcfmusp.remissive.sponsorship | Novartis | - |
hcfmusp.remissive.sponsorship | Otsuka | - |
hcfmusp.remissive.sponsorship | Pfizer | - |
hcfmusp.remissive.sponsorship | Servier | - |
hcfmusp.remissive.sponsorship | Stanley | - |
hcfmusp.lim.ref | 2012 | - |
hcfmusp.citation.scopus | 149 | - |
hcfmusp.scopus.lastupdate | 2024-04-12 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MPS Artigos e Materiais de Revistas Científicas - HC/IPq Artigos e Materiais de Revistas Científicas - LIM/21 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_GIGANTE_Brain_glutamate_levels_measured_by_magnetic_resonance_spectroscopy_2012.PDF Restricted Access | publishedVersion (English) | 310.46 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.